EPIRUS Biopharma (EPRS) Misses Q3 EPS by 8c; Updates on BOW015 as RA Treatment
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Comscore plans restructuring with $20M-$25M in cost cuts
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
EPIRUS Biopharmaceuticals Provides Clinical Program Update on BOW015 (Infliximab Biosimilar)
November 16, 2015 6:05 AM ESTReadiness for on-time initiation of pivotal global registration study with completion of manufacturing process lockBOW015 remains on track for 2017 global filingBOW015 targets large market opportunity based on $8.8 billion global sales of Remicade®i
BOSTON, Nov. 16, 2015 (GLOBE NEWSWIRE) -- Â EPIRUS Biopharmaceuticals, Inc. (Nasdaq: EPRS), a biopharmaceutical company focused on the global... More
EPIRUS Biopharmaceuticals Reports Third Quarter 2015 Financial Results & Provides Business Update
November 16, 2015 6:00 AM ESTBOSTON, Nov. 16, 2015 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq: EPRS), a biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies (mAbs), today reported financial results for the third quarter of 2015, and provided a business update.
This is an exciting time for EPIRUS as we bring monoclonal antibody biosimilars to patients worldwide and execute our global strategy of building a robust... More
